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Dilated perivascular space (dPVS) has recently been reported as a biomarker for cognitive impairment in Parkinson’s disease (PD).
However, comprehensive interrelationships between various clinical risk factors, dPVS, white-matter hyperintensities (WMH),
cognition, and motor function in PD have not been studied yet. The purpose of this study was to test whether dPVS might mediate
the effect of clinical risk factors on WMH, cognition, and motor symptoms in PD patients. A total of 154 PD patients were assessed
for vascular risk factors (hypertension, diabetes mellitus, and dyslipidemia), autonomic dysfunction (orthostatic hypotension and
supine hypertension [SH]), APOE ε4 genotype, rapid eye movement sleep-behavior disorder, motor symptoms, and cognition
status. The degree of dPVS was evaluated in the basal ganglia (BG) and white matter using a 5-point visual scale. Periventricular,
deep, and total WMH severity was also assessed. Path analysis was performed to evaluate the associations of these clinical factors
and imaging markers with cognitive status and motor symptoms. Hypertension and SH were significantly associated with more
severe BGdPVS, which was further associated with higher total WMH, consequently leading to lower cognitive status. More severe
BGdPVS was also associated with worse motor symptoms, but without mediation of total WMH. Similar associations were seen
when using periventricular WMH as a variable, but not when using deep WMH as a variable. In conclusion, BGdPVS mediates the
effect of hypertension and SH on cognitive impairment via total and periventricular WMH, while being directly associated with
more severe motor symptoms.
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INTRODUCTION
Parkinson’s disease (PD) has been primarily considered a motor
disorder, but cognitive impairment is also a common clinical
manifestation1. Various clinical and imaging biomarkers have been
reported as risk factors for cognitive impairment and motor
symptoms in PD. Vascular risk factors and imaging markers
representing small-vessel disease burden, such as white-matter
hyperintensities (WMH), have been seen to adversely affect
cognition and motor functions in PD2,3. Additionally, several
nonmotor symptoms, such as olfactory dysfunction4,5, depres-
sion6, autonomic dysfunction such as orthostatic hypotension
(OH) and supine hypertension (SH)1,4,7, and rapid eye movement
sleep-behavior disorder (RBD)5, have also been suggested as risk
factors for cognitive and motor impairment in PD. APOE ε4 allele
has also shown association with cognitive impairment in PD8.
Perivascular spaces are fluid-filled cavities surrounding the small
penetrating cerebral arterioles and venules. When visible on MRI,
these are considered to be dilated and functionally impaired.
Recently, dilated perivascular spaces (dPVS), particularly those
located in the basal ganglia (BGdPVS), have been emerging as an
imaging marker for cerebral small-vessel disease9. Increasing
evidence suggests possible links between dPVS, WMH, clinical risk
factors, and cognitive and motor symptoms in PD. In a long-
itudinal study10, the progression of WMH was associated with
higher BGdPVS burden at baseline. Among clinical risk factors,
hypertension is a well-established risk factor of BGdPVS as well as
of WMH9. OH11,12, and SH11, occasionally accompanied with OH,
have also been associated with WMH. The association between
sleep quality and dPVS13 suggests the possibility of RBD as a risk
factor for dPVS. The APOE ε4 allele is a risk factor for WMH14 and
has also been associated with dPVS15. Moreover, a recent
longitudinal study reported BGdPVS to be a predictor for cognitive
impairment in PD16, and a few case reports have suggested an
association between dPVS and parkinsonism17,18. Thus, we can
postulate that dPVS plays a potential role in mediating the effect
of clinical risk factors on WMH and cognitive and motor
symptoms in PD.
However, to the best of our knowledge, no study has evaluated
on the comprehensive interrelationships between clinical risk
factors, dPVS, WMH, cognition, and motor function in PD. We
therefore performed path analyses to evaluate whether dPVS




Among the 154 patients, who were predominantly drug-naive PD
(n= 116), 36 were diagnosed as PD-IC, 111 as PD-MCI, and seven
as PDD. PDD patients had more severe motor symptoms than PD-
IC patients. General cognitive function was the highest in the PD-
IC patients, followed by the PD-MCI and PDD patients. Among the
imaging markers, PDD patients showed more severe BGdPVS than
PD-IC and PD-MCI patients. PDD patients had higher periven-
tricular WMH burden than PD-IC patients (Table 1). Detailed
information on dPVS and WMH scores according to cognitive
status is shown in Supplementary Table 1.
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Interobserver reliability was good both for BGdPVS (κ= 0.74)
and white matter dPVS (WMdPVS) (κ= 0.71).
Path analyses
The variable-inflation factors were below four for all variables, so
we assumed that our variables had a low degree of
multicollinearity.
Prediction of cognitive status. When total WMH was used as a
variable, hypertension (β= 0.138, P= 0.045) and SH (β= 0.167,
P= 0.016) were significantly associated with severe BGdPVS.
Severe BGdPVS (β= 0.440, P < 0.001) was further associated with
higher total WMH, and higher total WMH (β= 0.188, P= 0.047)
was consequently related to poor cognitive status. Hypertension
(β= 0.270, P < 0.001) and absence of dyslipidemia (β=− 0.191,
P= 0.013) were associated with severe WMdPVS, but WMdPVS
was not significantly associated with WMH nor cognitive status
(Table 2, Fig. 1).
Similar results were found when periventricular WMH was used
as a variable instead of total WMH, showing significant associa-
tions between severe BGdPVS (β= 0.443, P < 0.001) and higher
periventricular WMH, and between higher periventricular WMH
(β= 0.199, P= 0.048) and poor cognitive status (Supplementary
Table 2, Supplementary Figure 1).
When deep WMH was used as a variable, severe BGdPVS
(β= 0.293, P= 0.001) and absence of OH (β=− 0.218, P= 0.005)
were associated with higher deep WMH, but there was no
significant association between deep WMH and cognitive status
(Supplementary Table 3).
Prediction of motor symptoms. When total WMH was used as a
variable, severe BGdPVS (β= 0.247, P= 0.007) was associated with
severe motor symptoms without being mediated by total WMH
(Table 2, Fig. 1).
When either periventricular WMH or deep WMH was used as a
variable instead of total WMH, severe BGdPVS (β= 0.210, P=
0.025 or β= 0.255, P= 0.003, respectively) was associated with
more severe motor symptoms without being mediated by
periventricular WMH or deep WMH, respectively (Supplementary
Tables 2 and 3, Supplementary Fig. 1).
Representative cases of BGdPVS and WMH being associated
with cognition and motor symptoms are shown in Fig. 2.
Reanalysis excluding PDD patients and combining them with PD-MCI
patients. The path analysis showed nearly identical trends for the
original analysis in which PD-MCI and PDD patients were analyzed
separately and the reanalysis in which PDD patients were either
excluded or combined with PD-MCI under a single label
(Supplementary Tables 4 and 5, respectively).
Table 1. Clinical and imaging characteristics of patients.
PD-IC (n= 36) PD-MCI (n= 111) PDD (n= 7) P Pa * Pb * Pc *
Clinical variables
Age, y 68.7 ± 7.9 70.2 ± 9.3 76.9 ± 7.2 0.085
Age at onset, y 65 (59–69) 67 (60–73) 73 (68–78) 0.092
Male 16 (44.4) 59 (53.2) 4 (57.1) 0.630
Education, y 12 (11–16) 12 (6–15) 12 (9–17) 0.189
Parkinsonism duration, m 12 (7–28) 12 (6–24) 24 (8–30) 0.777
Levodopa-equivalent dose, mg 0 (0–0) 0 (0–225) 0 (0–150) 0.097
UPDRS III 13 (13–20) 15 (10–21) 24 (19–27) 0.041 0.999 0.037 0.069
MMSE 29 (28–30) 27 (26–29) 23 (22–25) <0.001 0.001 <0.001 0.005
CCSIT 6.8 ± 2.4 6.0 ± 2.7 5.7 ± 3.0 0.250
Depression 21 (58.3) 57 (51.4) 6 (85.7) 0.182
OH 6 (16.7) 22 (19.8) 2 (28.6) 0.756
SH 1 (2.8) 11 (9.9) 1 (14.3) 0.348
RBD 8 (22.2) 44 (39.6) 2 (28.6) 0.153
APOE ε4 carrier 7 (19.4) 22 (18.8) 1 (14.3) 0.938
Vascular risk factors
Hypertension 17 (47.2) 45 (40.6) 4 (57.1) 0.575
Diabetes mellitus 9 (25.0) 15 (13.5) 3 (42.9) 0.062
Dyslipidemia 22 (61.1) 56 (50.5) 3 (42.9) 0.468
Imaging findings
BGdPVS 1 (1–2) 2 (1–2) 3 (2–4) 0.010 0.901 0.009 0.027
WMdPVS 3 (2–4) 3 (2–4) 3 (2–4) 0.779
Total WMH 2 (1–2) 2 (2–3) 4 (2–4) 0.016 0.055 0.102 0.493
Periventricular WMH 1 (1–1) 1 (1–2) 3 (1–3) 0.020 0.160 0.047 0.215
Deep WMH 1 (0–1) 1 (1–1) 1 (1–1) 0.106
Data are expressed as means ± standard deviations or medians with interquartile ranges or as numbers with percentages in parentheses.
P refers to the statistical significance among the three groups.
*Pa, Pb, and Pc refer to the corrected statistical significance with Bonferroni-like adjustment for differences between the PD-IC and PD-MCI, PD-IC and PDD, and
PD-MCI and PDD groups, respectively.
Abbreviations: BG basal ganglia, CCSIT Cross-Cultural Smell Identification Test, dPVS dilated perivascular space, MMSE Mini-Mental State Examination, OH
orthostatic hypotension, PDD PD with dementia, PD-IC PD with intact cognition, PD-MCI PD with mild cognitive impairment, RBD REM sleep behavior disorder,
SH supine hypertension, UPDRS III Unified Parkinson’s Disease Rating Scale III, WM white matter, WMH white matter hyperintensities.
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The present study examined the clinical effect of dPVS related to
vascular and autonomic risk factors, RBD, APOE ε4 genotype, and
WMH, with adjustment of known demographic and clinical risk
factors. Our study resulted in three major findings. First, among
the various clinical risk factors, hypertension and SH were
significantly associated with BGdPVS. Second, BGdPVS mediated
the effect of hypertension and SH on cognitive status via WMH or
directly on motor symptoms without mediation of WMH. Third,
the effect of WMH on cognition was driven by periventricular
WMH, while deep WMH did not significantly affect cognition.
In line with previous results2,9, hypertension was significantly
associated with higher BGdPVS and WMH in our study. More
importantly, we found SH to be a novel risk factor for BGdPVS and
an indirect one for WMH. Over the past few decades, OH rather
than SH has received more attention as a risk factor for WMH,
which is itself an imaging marker for small-vessel disease12,19,20.
However, most studies did not consider the coexistence of SH19,20,
while others suggested a greater association between SH and
WMH than between OH and WMH12,21. Our study supports the
latter studies, as our findings suggest SH to be more important in
the pathogenesis of small-vessel disease. The vascular damage
caused by high blood pressure when OH patients have SH may be
more crucial in the development of cerebral small-vessel disease
than the ischemic damage due to episodic hypotension asso-
ciated with OH22. A recent study also found that SH in patients
with OH was associated with a higher burden of target organ
damage including cerebral small-vessel disease23.
In our study, WMH was significantly associated with only
cognitive status, while BGdPVS was associated with both cognitive
and motor symptoms. The association between WMH and
cognition has been relatively consistent in previous literature24,25,
while reports on its association with motor symptoms have been
conflicting26,27. Therefore, BGdPVS may serve as a more useful
imaging marker when predicting both symptoms. The effect of
BGdPVS was mediated via WMH for cognition, whereas it directly
affected motor function without WMH mediation. Although the
reason for this phenomenon is unclear, a previous autopsy study
of patients with parkinsonian symptoms reported decreased
neuronal and axonal densities with reactive gliosis in BG adjacent
to BGdPVS28. As BG plays a crucial role in motor function, we can
postulate that parenchymal alterations accompanying BGdPVS
might directly worsen motor symptoms in PD.
Our results were also similar to previous findings that suggested
periventricular WMH rather than deep WMH as being associated
with cognition in various populations24,25. Periventricular WM
contains a higher density of long-association and projection fiber
tracts that connect with more distant cortical areas and subcortical
regions than the more superficially located deep WM as its fibers
radiate to the cortical areas with a fan-like shape29. Given that
effective communications with long distant cortical areas and
subcortical regions are crucial to maintaining a normal cognitive
process30, an association between periventricular WMH and
cognition is understandable. Another possible explanation is that
periventricular WMH may disrupt periventricular corticopetal
cholinergic nerve fibers arising from the nucleus basalis of
Meynert, which plays an important role in cognition31.
In contrast to previous results32,33, we failed to find significant
associations between the presence of RBD with poor cognitive
and motor symptoms. We also could not associate RBD and dPVS
burden, while some previous studies have reported decreased
sleep efficiency in PD patients with RBD34 and poor sleep
Table 2. Effects of predictors on cognitive status and motor symptoms through mediators when total WMH was used as a variable.
BGdPVS WMdPVS Total WMH Cognitive status UPDRSIII
β SE P β SE P β SE P β SE P β SE P
Hypertension 0.138 0.148 0.045 0.270 0.158 <0.001 0.033 0.153 0.640 −0.026 0.083 0.754 −0.126 1.435 0.097
Diabetes mellitus −0.071 0.194 0.313 −0.140 0.206 0.069 0.029 0.193 0.674 −0.030 0.104 0.711 0.014 1.808 0.852
Dyslipidemia −0.070 0.148 0.318 −0.191 0.157 0.013 0.013 0.148 0.847 −0.066 0.080 0.415 −0.100 1.391 0.179
OH −0.097 0.190 0.170 −0.025 0.202 0.744 −0.073 0.187 0.289 0.020 0.102 0.806 0.120 1.762 0.109
SH 0.167 0.266 0.016 0.083 0.283 0.276 0.036 0.266 0.599 0.069 0.145 0.396 −0.047 2.501 0.529
RBD 0.047 0.160 0.514 0.079 0.170 0.316 −0.003 0.157 0.971 0.111 0.085 0.173 0.032 1.474 0.675
APOE ε4 carrier 0.103 0.183 0.136 −0.052 0.195 0.491 0.00 0.181 0.916 −0.023 0.098 0.776 −0.088 1.697 0.225
BGdPVS 0.440 0.079 <0.001 0.044 0.047 0.664 0.247 0.810 0.007
WMdPVS −0.031 0.074 0.663 −0.020 0.040 0.812 −0.105 0.695 0.168
Total WMH 0.188 0.044 0.047 −0.046 0.753 0.593
Age, sex, years of education, disease duration, levodopa-equivalent dose, CCSIT score, and the presence of depression were used as covariates.
Abbreviations: β standardized beta coefficient, BG basal ganglia, dPVS dilated perivascular spaces, OH orthostatic hypotension, RBD REM sleep behavior
disorder, SE standard error, SH supine hypertension, UPDRS III Unified Parkinson’s Disease Rating Scale III, WM white matter, WMH white matter
hyperintensities.
Fig. 1 Schematic diagram of path analyses for cognitive status
and motor symptoms. Vascular risk factors (hypertension, diabetes
mellitus, and dyslipidemia), autonomic risk factors (OH, SH), RBD,
and APOE ε4 status were entered as predictors. BGdPVS, WMdPVS,
and total WMH were entered as mediators. Age, sex, years of
education, disease duration, levodopa-equivalent dosage, CCSIT
score, and the presence of depression were entered as covariates.
Numbers on the paths are the standardized coefficients that were
statistically significant. Abbreviations: BG basal ganglia, dPVS dilated
perivascular spaces, CCSIT Cross-Cultural Smell Identification Test,
HTN hypertension, OH orthostatic hypotension, RBD REM sleep-
behavior disorder, SH supine hypertension, WM white-matter, WMH
white matter hyperintensities.
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efficiency with increased dPVS burden13, possibly due to
decreased glymphatic function that increases during sleep35.
These discordant results might be, at least in part, attributable to
the inclusion of various clinical and imaging variables as covariates
in our study, because when only age, sex, and education were
included as covariates, RBD was found as an independent
predictor of PD-MCI (β= 0.440, P= 0.044, not shown). However,
as the association of RBD with WMH or dPVS has seldom been
studied, further studies are warranted.
The presence of the APOE ε4 allele was also not associated with
cognitive and motor symptoms nor imaging markers in our study.
Although the APOE ε4 allele is thought to play an important role in
the cognitive impairment of PD8, some studies have failed to find
a significant contribution of the APOE ε4 allele in the cognitive
decline of PD36. Reports about the APOE ε4 allele and WMdPVS
are also inconsistent: significant association was reported in an
autopsy study37, while an MRI study failed to find any such
associations38. Inherent limits due to the spatial resolution of MRI
and visual assessment of dPVS with a 5-point scale might account
for these inconsistent results. Objective and quantitative assess-
ment of dPVS imaged with high-resolution MRI might provide
more conclusive results.
Although WMdPVS and deep WMH burdens did not signifi-
cantly affect cognitive or motor symptoms in our PD patients, it is
noteworthy that they show the same risk factors as well as
different risk factors with BGdPVS and periventricular WMH,
respectively. These findings suggest a common and distinct
pathophysiology of dPVS and WMH according to location, and
further studies are required to elucidate this possibility.
There are several limitations to our study. First, it is a cross-
sectional, retrospective study, with a small number of PDD
patients. Therefore, prospective studies with larger populations
are warranted. Second, we only performed a qualitative analysis of
dPVS and WMH. Although our analyzing methods are simple to
perform with high interrater reliability, which allows their easy
application in practical clinical workflow, future studies with
objective and quantitative assessments of dPVS may offer new
insights into the pathophysiology and clinical implications of
dPVS. Therefore, automated and easy-to-use methods should
continue to be developed. Third, because path analysis cannot be
used to establish causality between variables39, future longitudinal
studies are warranted to assess the causality between dPVS, WMH,
and cognitive or motor symptoms in PD. Fourth, because dPVS
has been shown to increase with age40, the older age of PD
patients with cognitive impairment may be a confounding factor.
Although adjustments were made for age in the analysis, future
studies still need to consider the association between dPVS and
age. Fifth, we used rather liberal criteria for defining “abnormal”
outcomes of each neuropsychological test by using the one-
standard-deviation cut-off value as well as for diagnosing
Fig. 2 Representative cases showing the associations of BGdPVS and WMH with cognitive status and motor symptoms. a A 72-year-old
male diagnosed as PD-IC, with a UPDRS III score of 4. The patient did not have a history of hypertension or SH. The axial T2-weighted images
show a BGdPVS score of 1. On FLAIR images, the total Fazekas score of WMH was 1. b A 79-year-old male diagnosed with PDD, with a UPDRS III
score of 15. The patient had hypertension and SH. The axial T2-weighted images show BGdPVS score of 4. On FLAIR images, the total Fazekas
score of WMH was 4. Abbreviations: BG basal ganglia, dPVS dilated perivascular spaces, FLAIR fluid-attenuated inversion recovery, PD-IC PD
with intact cognition, PDD PD with dementia, SH supine hypertension, UPDRS III Unified Parkinson’s Disease Rating Scale Part III, WMH white-
matter hyperintensities.
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“PD–MCI” with the abbreviated assessment of level I criteria,
although these criteria were considered acceptable by the
Movement Disorder Society Task Force41. Therefore, our results
must be interpreted with caution as false-positive diagnoses
cannot be ruled out for PD-MCI. Sixth, because MRI exams were
usually performed to diagnose PD and neuropsychological tests
were usually performed when patients had cognitive complaints,
most patients who underwent both MRI and neuropsychological
tests were PD-MCI patients and the proportions of PD-IC and PDD
patients in our dataset were relatively small, which may have led
to biased results. Despite these limitations, the strength of our
study is that we found significant associations between hyperten-
sion and SH with BGdPVS, WMH, and cognitive or motor
symptoms in PD patients even after adjusting for known clinical
and imaging risk factors. Our results also have clinical implications
as hypertension and SH are suggested as possible therapeutic
targets to prevent or slow down the deterioration of cognitive and
motor symptoms in PD patients, although a longitudinal study
that assesses the effect of these treatments is warranted.
In conclusion, BGdPVS mediates the effect of hypertension and
SH on cognitive impairment via total and periventricular WMH,
whereas it is directly associated with severe motor symptoms. Our
results indicate that BGdPVS adversely affects both cognitive and




This study was approved by the Institutional Review Board of the Catholic
University of Korea, Catholic Medical Center, Seoul St. Mary’s Hospital, and
was issued a waiver of informed consent due to its retrospective design.
PD patients who underwent MRI from April 2015 to August 2018 and who
were assessed for cognitive status and motor symptoms within six months
of MRI were selected from a prospectively collected movement disorders
and dementia registry of a single tertiary hospital. Exclusion criteria were as
follows: (1) incomplete clinical data (n= 33) and (2) the presence of large
old infarcts or hemorrhage on MRI (n= 5). Thus, a total of 154 patients (79
males; mean age ± standard deviation, 70.2 ± 9.0) were included in the
final study population (Supplementary Fig. 2). As MRI exams are usually
performed when diagnosing PD in our institution, most of the patients
enrolled in our study were relatively newly diagnosed PD patients.
PD was diagnosed according to the United Kingdom PD Society Brain
Bank. Motor symptoms were assessed using the Unified Parkinson’s
Disease Rating Scale Part III (higher scores represent more severe motor
symptoms). In patients taking medication (n= 38), assessments were
performed in the medication-on state. Cognitive status was determined
using the Seoul Neuropsychological Screening Battery42, and the out-
comes were defined as abnormal when the scores of each test were below
the one-standard-deviation of the age-, sex-, and education-matched
norms. PD-mild cognitive impairment (PD-MCI) and PD dementia (PDD)
were diagnosed according to the Movement Disorder Society Task Force
diagnostic criteria for PD-MCI level I and probable PDD, respectively41,43.
PD medication doses were calculated as levodopa equivalents. The
presence of vascular risk factors and APOE ε4 allele was assessed.
Depressive symptoms were evaluated using the Geriatric Depression Scale
or its short form with a cut-off value of 9/10 or 4/5 for defining depression,
respectively44. The REM Sleep Behavior Disorder Screening Questionnaire
(RBDSQ) with the primary question on RBD (question 1) of the Mayo Sleep
Questionnaire (MSQ) or polysomnography was used to determine the
presence of RBD. Patients with RBDSQ scores of 5 or more with affirmative
responses to the MSQ question 145 or polysomnographic REM sleep
without atonia46 were defined as having RBD. Olfactory function was also
assessed using the Cross-Cultural Smell Identification Test (higher scores
represent higher performances). More details on the diagnostic criteria for
vascular risk factors and cognitive status are in Supplementary Methods.
To diagnose OH and SH, the head-up tilt test was performed. Systolic
and diastolic blood pressures were measured after patients had been in
the supine position for 20min and the lowest systolic and diastolic blood
pressures were selected among measurements made 3 or 5min after
patients had begun the 60° tilted position, respectively. Then, orthostatic
changes in the systolic (ΔSBP) and diastolic (ΔDBP) blood pressures were
calculated. SH was defined with a SBP of 150mm Hg or higher, or a DBP of
90mm Hg or higher, with patients in the supine position47. OH was
defined as an orthostatic ΔSBP ≥ 20mmHg or ΔDBP ≥ 10mmHg in patients
without SH and as an orthostatic ΔSBP ≥ 30mmHg or ΔDBP ≥ 15mmHg in
patients with SH48.
MRI acquisition
MRI scans were acquired using a 3 T scanner (MAGNETOM Verio; Siemens
Healthineers Sector, Erlangen, Germany) with a 12-channel coil. The MRI
imaging protocol included two-dimensional axial T2-weighted and FLAIR
images (parameters in Supplementary Methods).
Analysis of dPVS
dPVS were assessed on T2-weighteed images according to STRIVE
recommendations49, and rated in the basal ganglia (BG) and white matter
(WM), respectively, using a validated 5-point visual rating scale (0= absent
dPVS, 1= less than 10 dPVS, 2= 11–20 dPVS, 3= 21–40 dPVS, 4=more
than 40 dPVS)50 by a neuroradiologist with eight years of experience who
was blinded to clinical data. The number of dPVS was counted in each
hemisphere, and the highest score was recorded. Another neuroradiologist
with 14 years of experience who was also blinded to clinical data rated the
BGdPVS and WMdPVS in 30 randomly selected patients to assess
interobserver agreements.
Analysis of WMH
WMH were defined as hyperintense white-matter lesions on FLAIR images
according to the STRIVE criteria49, and graded in accordance with the
Fazekas scale by a neuroradiologist with eight years of experience who
was blinded to clinical data. Periventricular and deep WMHs were rated
separately. Periventricular WMH were scored as follows: 0= absence, 1=
caps or pencil-thin lining, 2= smooth halo, and 3= irregular WMH
extending into deep white matter. Deep WMH were scored as follows:
0= absence, 1= punctate, 2= early confluent, and 3= confluent. The
scores for periventricular and deep WMH were added to calculate the total
Fazekas score (0–6)51.
Statistical analysis
According to normality test results, quantitative data were analyzed with
either ANOVA or the Kruskal–Wallis test to compare the three groups. The
Chi-squared test or Fisher’s exact test was used to analyze categorical data.
A post hoc analysis was also performed using the Mann–Whitney U test,
Chi-squared test, or Fisher’s exact test with Bonferroni-like adjustment for
multiple comparisons. Inter-observer agreements for dPVS rating were
analyzed using the weighted Cohen kappa coefficient.
Path analyses were performed to evaluate whether dPVS mediated the
effects of vascular risk factors (hypertension, diabetes mellitus, and
dyslipidemia), autonomic abnormalities (OH and SH), APOE ε4 status,
and RBD on total WMH and cognition. Path analysis was used to
simultaneously consider the direct, indirect, and total effects of predictors
on outcomes through mediators. Cognitive status was labeled as the
outcome (PD-intact cognition [PD-IC] was labeled as 0, PD-MCI as 1, and
PDD as 2). Age, sex, education, disease duration, levodopa-equivalent dose,
the Cross-Cultural Smell Identification Test score, and depression were
used as covariates. An identical process was performed by using either
periventricular WMH or deep WMH as a variable instead of total WMH, to
assess the differential role of WMH on cognition status according to
location.
To evaluate whether dPVS mediates the effects of clinical risk factors on
motor symptoms, path analyses were performed identically for cognitive
status, except when the Unified Parkinson’s Disease Rating Scale Part III
score was considered the outcome.
In addition, because there were few PDD patients available for analysis,
we needed to determine if this small group inappropriately drove the
results. The data were reanalyzed, first excluding PDD, and second
combining PD-MCI and PDD under a single label.
The variance-inflation factor was used to detect multicollinearity
between variables. A P value <0.05 was considered statistically significant.
All statistical analyses were performed using SPSS (version 24; IBM Corp.,
Armonk, NY, USA).
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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